overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
Company profile
Ticker
OTLK
Exchange
Website
CEO
Lawrence Kenyon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Oncobiologics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Outlook Therapeutics Pty Ltd • Outlook Therapeutics Limited • This list does not include joint ventures in which the Company ...
OTLK stock data
Latest filings (excl ownership)
D
$13.25 mm in equity / options / securities to be acquired, sold $5.00 mm, 1 investor
16 Apr 24
8-K
Unregistered Sales of Equity Securities
15 Apr 24
424B5
Prospectus supplement for primary offering
12 Apr 24
8-K
Other Events
12 Apr 24
EFFECT
Notice of effectiveness
8 Apr 24
8-K
Other Events
2 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
424B3
Prospectus supplement
1 Apr 24
D
$159.00 mm in equity / options / securities to be acquired, sold $60.00 mm, 21 investors
29 Mar 24
S-8
Registration of securities for employees
28 Mar 24
Latest ownership filings
SC 13D/A
Syntone Ventures LLC
17 Apr 24
4
Change in insider ownership
17 Apr 24
SC 13G
GREAT POINT PARTNERS LLC
8 Apr 24
4
Yezan Munther Haddadin
29 Mar 24
SC 13G
Velan Capital Investment Management LP
28 Mar 24
SC 13G
TANG CAPITAL PARTNERS LP
28 Mar 24
4
C RUSSELL TRENARY III
22 Mar 24
4
Jeff Evanson
22 Mar 24
4
LAWRENCE A KENYON
22 Mar 24
SC 13D/A
GMS Ventures & Investments
20 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.39 mm | 23.39 mm | 23.39 mm | 23.39 mm | 23.39 mm | 23.39 mm |
Cash burn (monthly) | 3.44 mm | (no burn) | 4.33 mm | 4.93 mm | 4.25 mm | 3.58 mm |
Cash used (since last report) | 22.92 mm | n/a | 28.86 mm | 32.86 mm | 28.31 mm | 23.87 mm |
Cash remaining | 469.05 k | n/a | -5.47 mm | -9.47 mm | -4.92 mm | -478.03 k |
Runway (months of cash) | 0.1 | n/a | -1.3 | -1.9 | -1.2 | -0.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 80 |
Opened positions | 13 |
Closed positions | 19 |
Increased positions | 25 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 6.14 bn |
Total shares | 141.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ventures & Investments GMS | 71.28 mm | $71.99 mm |
BioLexis Pte | 22.98 mm | $25.28 mm |
Syntone Ventures | 19.82 mm | $29.14 mm |
BLK Blackrock | 9.39 mm | $2.08 bn |
Vanguard | 6.28 mm | $1.39 bn |
STT State Street | 2.79 mm | $616.54 mm |
Geode Capital Management | 2.78 mm | $615.22 mm |
NTRS Northern Trust | 1.26 mm | $277.65 mm |
BNP Paribas Arbitrage | 521.84 k | $115.33 mm |
BK Bank Of New York Mellon | 434.57 k | $96.04 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Syntone Ventures | Common Stock | Buy | Acquire P | No | No | 0 | 714,286 | 0.00 | 1,705,438 |
15 Apr 24 | Syntone Ventures | Warrant Common Stock | Buy | Acquire P | No | No | 7.7 | 1,071,429 | 8.25 mm | 1,071,429 |
28 Mar 24 | Haddadin Yezan Munther | Common Stock | Buy | Acquire P | No | No | 11.82 | 1,881.711 | 22.24 k | 5,048.711 |
20 Mar 24 | C Russell Trenary Iii | Stock Option Common Stock | Grant | Acquire A | No | No | 6.78 | 455,000 | 3.08 mm | 455,000 |
20 Mar 24 | Evanson Jeff | Stock Option Common Stock | Grant | Acquire A | No | No | 6.78 | 25,000 | 169.50 k | 25,000 |
20 Mar 24 | Kenyon Lawrence A | Stock Option Common Stock | Grant | Acquire A | No | No | 6.78 | 12,500 | 84.75 k | 12,500 |
News
Insiders Buying Outlook Therapeutics And 2 Other Stocks
1 Apr 24
BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target
27 Mar 24
HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Adjusts Price Target To $30 (reverse stock split 1:20)
25 Mar 24
Gold Moves Lower; Lululemon Shares Plummet
22 Mar 24
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
22 Mar 24
Press releases
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
15 Apr 24
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
22 Mar 24
Thinking about buying stock in Mind Medicine, Ocean Biomedical, Archer Aviation, Outlook Therapeutics, or Cardiff Oncology?
15 Mar 24
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
14 Feb 24
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
31 Jan 24